FIELD: medicine, obstetrics in particular.
SUBSTANCE: invention relates to medicine, namely to obstetrics, and can be used to predict the risk of developing preeclampsia in pregnant women with type 1 and type 2 diabetes. A blood serum test is performed by an enzyme immunoassay at the early stages of pregnancy. Determined is the content of endoglin in the peripheral blood serum at 11-14 weeks of pregnancy. When its value is equal to or more than 274 ng/ml, a high risk of developing preeclampsia is predicted.
EFFECT: method makes it possible to predict preeclampsia in pregnant women with concomitant type 1 and 2 diabetes mellitus at the early stages of pregnancy of 11-14 weeks with great accuracy, specificity and simplicity of implementation by determining the content of endoglin - a receptor for TGF-beta in the blood serum, since an increase in the content of the circulating soluble form of endoglin leads to increased vasoconstriction and increased blood pressure.
1 cl, 1 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 1 DIABETES MELLITUS | 2022 |
|
RU2800717C1 |
| METHOD FOR PREDICTION OF RISK OF DEVELOPING PREECLAMPSIA IN PREGNANT WOMEN WITH VARIOUS TYPES OF DIABETES MELLITUS | 2021 |
|
RU2767912C1 |
| METHOD OF PREDICTING THE RISK OF PRE-ECLAMPSIA IN PREGNANT WOMEN WITH TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2800716C1 |
| METHOD FOR PREDICTION OF EARLY AND LATE PREECLAMPSIA | 2018 |
|
RU2693412C1 |
| METHOD FOR PREDICTION OF PREECLAMPSIA IN PREGNANT WOMEN WITH GESTATIONAL DIABETES MELLITUS | 2020 |
|
RU2740852C1 |
| METHOD FOR PREDICTING MACROSOMIA IN PREGNANT WOMEN WITH ANDROID-TYPE OBESITY IN THE FIRST TRIMESTER OF PREGNANCY | 2021 |
|
RU2779994C1 |
| METHOD FOR PREDICTING THE RECURRENCE OF EARLY PREECLAMPSIA BY MARKERS OF ENDOTHELIAL DYSFUNCTION | 2022 |
|
RU2795090C1 |
| METHOD FOR PREDICTION OF THE RISK OF DEVELOPING SEVERE COMPLICATIONS OF PREECLAMPSIA | 2020 |
|
RU2741730C1 |
| PREDICTION OF PREECLAMPSIA BASED ON DETERMINING EXTRACELLULAR FETAL DNA IN MATERNAL BLOOD WHEN SCREENING THE FIRST TRIMESTER OF PREGNANCY | 2019 |
|
RU2697845C1 |
| METHOD FOR FORMING RISK GROUP OF PRE-ECLAMPSIA | 2021 |
|
RU2762204C1 |
